<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Diagnostic approach to and treatment of thyroid nodules</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Diagnostic approach to and treatment of thyroid nodules</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Diagnostic approach to and treatment of thyroid nodules</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Douglas S Ross, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David S Cooper, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jean E Mulder, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 07, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Thyroid nodules come to clinical attention when noted by the patient; by a clinician during routine physical examination; or during a radiologic procedure, such as carotid ultrasonography, neck or chest computed tomography (CT), or positron emission tomography (PET) scanning. Their clinical importance is primarily related to the need to exclude thyroid cancer, which accounts for 4 to 6.5 percent of all thyroid nodules in nonsurgical series.</p><p>The diagnostic evaluation and treatment of thyroid nodules will be reviewed here. Fine-needle aspiration (FNA) techniques, common cytopathologic findings, and evaluation and management issues specific to indeterminate cytologies, are reviewed elsewhere.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7889.html" rel="external">"Thyroid biopsy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7823.html" rel="external">"Atlas of thyroid cytopathology"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/116428.html" rel="external">"Evaluation and management of thyroid nodules with indeterminate cytology in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph utd-adt-cnt utd-adt-pathwys">●</span><span class="utd-adt-cnt utd-adt-pathwys utd-content-120428">(Related Pathway(s):  <a class="utd-content-120428" href="/pathway/120428?topicRef=7890&amp;source=see_link">Thyroid nodules: Initial evaluation in adults</a>.)</span></p><p></p><p class="bulletIndent1"><span class="glyph utd-adt-cnt utd-adt-pathwys">●</span><span class="utd-adt-cnt utd-adt-pathwys utd-content-120429">(Related Pathway(s):  <a class="utd-content-120429" href="/pathway/120429?topicRef=7890&amp;source=see_link">Thyroid nodules: Initial evaluation in pregnant patients</a>.)</span></p><p></p><p class="headingAnchor" id="H2"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>Several different disorders can cause thyroid nodules  (<a class="graphic graphic_table graphicRef57701" href="/d/graphic/57701.html" rel="external">table 1</a>). The clinical importance of the thyroid nodule evaluation is primarily related to the need to exclude thyroid cancer, which is present in 4 to 6.5 percent of thyroid nodules [<a href="#rid1">1-5</a>]. The prevalence of cancer is higher in several groups:</p><p class="bulletIndent1"><span class="glyph">●</span>Children</p><p class="bulletIndent1"><span class="glyph">●</span>Adults less than 30 years of age</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with a history of head and neck irradiation</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with a family history of thyroid cancer</p><p></p><p>In one study from Sicily [<a href="#rid2">2</a>], but not in another study from Boston [<a href="#rid5">5</a>], the prevalence of cancer was higher in adults over 60 years.</p><p>Our approach  (<a class="graphic graphic_algorithm graphicRef90862" data-inline-graphics="90862" href="/d/graphic/90862.html" rel="external">algorithm 1</a>) described below is consistent with the American Thyroid Association (ATA) and the National Comprehensive Cancer Network (NCCN) guidelines [<a href="#rid6">6,7</a>]. <span class="utd-adt-cnt utd-adt-pathwys utd-content-120429 utd-content-120428">(Related Pathway(s):  <a class="utd-content-120429" href="/pathway/120429?topicRef=7890&amp;source=see_link">Thyroid nodules: Initial evaluation in pregnant patients</a> and  <a class="utd-content-120428" href="/pathway/120428?topicRef=7890&amp;source=see_link">Thyroid nodules: Initial evaluation in adults</a>.)</span></p><p class="headingAnchor" id="H1584452"><span class="h2">Initial</span><span class="headingEndMark"> — </span>Thyroid nodules come to clinical attention when noted by the patient; during routine physical examination; or when incidentally noted during a radiologic procedure, such as carotid ultrasonography, neck or chest computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET) scanning. Nonpalpable nodules (incidentalomas) have the same risk of malignancy as palpable nodules of the same size [<a href="#rid8">8-11</a>]. Thus, the initial evaluation in all patients with a thyroid nodule (discovered either by palpation or incidentally noted on a radiologic procedure) includes:</p><p class="bulletIndent1"><span class="glyph">●</span>History and physical examination</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Measurement of serum thyroid-stimulating hormone (TSH)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ultrasound to confirm the presence of nodularity, assess sonographic features, and assess for the presence of additional nodules and lymphadenopathy</p><p></p><p class="headingAnchor" id="H3"><span class="h3">History and physical examination</span><span class="headingEndMark"> — </span>The history and physical examination have a low accuracy for predicting cancer. However, there are several features of the history that suggest an increased likelihood of malignancy, such as a history of rapid growth of a neck mass, childhood head and neck irradiation, total body irradiation for bone marrow transplantation, family history of thyroid cancer, or thyroid cancer syndromes (eg, multiple endocrine neoplasia type 2 [MEN2], familial adenomatous polyposis, or Cowden syndrome). (See  <a class="medical medical_review" href="/d/html/16543.html" rel="external">"PTEN hamartoma tumor syndromes, including Cowden syndrome"</a> and  <a class="medical medical_review" href="/d/html/2593.html" rel="external">"Clinical manifestations and diagnosis of familial adenomatous polyposis"</a> and  <a class="medical medical_review" href="/d/html/7870.html" rel="external">"Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2"</a>.)</p><p>The physical examination findings of a fixed hard mass, obstructive symptoms, cervical lymphadenopathy, or vocal cord paralysis all suggest the possibility of cancer.</p><p class="headingAnchor" id="H4"><span class="h3">Serum TSH</span><span class="headingEndMark"> — </span>Thyroid function should be assessed in all patients with thyroid nodules  (<a class="graphic graphic_algorithm graphicRef90862" href="/d/graphic/90862.html" rel="external">algorithm 1</a>). (See <a class="local">'TSH low'</a> below and <a class="local">'TSH normal or high'</a> below.)</p><p>Serum TSH is an independent risk factor for predicting malignancy in a thyroid nodule. In a study of 1500 patients presenting to a thyroid practice, the prevalence of malignancy was 2.8, 3.7, 8.3, 12.3, and 29.7 percent for patients with serum TSH concentrations &lt;0.4 mU/L, 0.4 to 0.9 mU/L, 1 to 1.7 mU/L, 1.8 to 5.5 mU/L, and &gt;5.5 mU/L, respectively [<a href="#rid12">12</a>]. Other studies have shown that when cancer was diagnosed, a higher TSH was associated with a more advanced stage of cancer [<a href="#rid13">13,14</a>].</p><p class="headingAnchor" id="H5"><span class="h3">Thyroid ultrasonography</span><span class="headingEndMark"> — </span>Thyroid ultrasound should be performed in all patients with a suspected thyroid nodule or nodular goiter on physical examination or with nodules incidentally noted on other imaging studies (carotid ultrasound, CT, MRI, or fludeoxyglucose [FDG]-PET scan). The routine use of thyroid ultrasound as a screening tool to detect nonpalpable thyroid cancers in patients without known or suspected thyroid nodules is not recommended [<a href="#rid7">7,15</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Provides more information than physical examination</strong> – Thyroid ultrasonography is used to answer questions about the size and anatomy of the thyroid gland and adjacent structures in the neck. It provides considerably more anatomic detail than thyroid scintigraphy [<a href="#rid16">16</a>], CT [<a href="#rid17">17</a>], and physical examination [<a href="#rid18">18,19</a>]. (See  <a class="medical medical_review" href="/d/html/7859.html" rel="external">"Overview of the clinical utility of ultrasonography in thyroid disease", section on 'Nodule identification and characterization'</a>.)</p><p></p><p class="bulletIndent1">In a retrospective study of 173 patients referred to a thyroid nodule clinic for an abnormal thyroid examination, the ultrasound findings were different from the physical examination done by the referring clinician in 63 percent of cases [<a href="#rid19">19</a>]. Of the 114 patients referred for a solitary nodule, 24 percent had additional nodules and 20 percent did not have a nodule of at least 1 cm that required aspiration. (See <a class="local">'Sonographic criteria for FNA'</a> below.)</p><p></p><p class="bulletIndent1">Ultrasound can identify posteriorly located nodules or predominantly cystic nodules. The diagnostic accuracy of FNA performed by palpation is reduced in these nodules, and ultrasound-guided FNA is more effective (see  <a class="medical medical_review" href="/d/html/7889.html" rel="external">"Thyroid biopsy", section on 'Ultrasound guidance'</a>). Apparent nodularity in Hashimoto's thyroiditis may represent focal enlargement from lymphocytic infiltrates, TSH-induced hyperplasia of follicular tissue, or a thyroid tumor. Ultrasonography may also help to distinguish among these possibilities.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Helps select nodules for FNA</strong> – There are several ultrasonographic findings that are suspicious for thyroid cancer  (<a class="graphic graphic_table graphicRef68199" href="/d/graphic/68199.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef120691" href="/d/graphic/120691.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef70513" href="/d/graphic/70513.html" rel="external">table 4</a>). The predictive value of these characteristics varies widely, and we do not rely on thyroid ultrasound to diagnose cancer or to select patients for surgery. However, ultrasound findings can be used to select nodules for FNA biopsy. (See <a class="local">'Sonographic criteria for FNA'</a> below and  <a class="medical medical_review" href="/d/html/7859.html" rel="external">"Overview of the clinical utility of ultrasonography in thyroid disease", section on 'Criteria for identifying cancer'</a>.)</p><p></p><p class="headingAnchor" id="H1584486"><span class="h2">Subsequent evaluation</span><span class="headingEndMark"> — </span>Subsequent evaluation is based upon the TSH level and sonographic features of the nodule(s)  (<a class="graphic graphic_algorithm graphicRef90862" href="/d/graphic/90862.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H1584479"><span class="h3">TSH low</span><span class="headingEndMark"> — </span>If the serum TSH concentration is subnormal, indicating overt or subclinical hyperthyroidism, the possibility that the nodule is hyperfunctioning is increased and thyroid scintigraphy should be performed next  (<a class="graphic graphic_algorithm graphicRef90862" href="/d/graphic/90862.html" rel="external">algorithm 1</a>). Thyroid hormone production from some autonomous nodules may suppress TSH only within the lower portion of the normal range (eg, &lt;1 mU/L). Scintigraphy may be informative in such patients, especially if prior TSH levels were subnormal, or when the results of an FNA suggest a follicular neoplasm. (See <a class="local">'Thyroid scintigraphy'</a> below and  <a class="medical medical_review" href="/d/html/116428.html" rel="external">"Evaluation and management of thyroid nodules with indeterminate cytology in adults"</a>.)</p><p>Patients with TSH below the normal range also require an evaluation for hyperthyroidism. (See  <a class="medical medical_review" href="/d/html/7847.html" rel="external">"Diagnosis of hyperthyroidism", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H6"><span class="h4">Thyroid scintigraphy</span><span class="headingEndMark"> — </span>Thyroid scintigraphy is used to determine the functional status of a nodule. A subnormal serum TSH, indicating overt or subclinical hyperthyroidism, increases the possibility that a thyroid nodule is hyperfunctioning. Since hyperfunctioning nodules rarely are cancer, a nodule that is hyperfunctioning on radioiodine imaging does not require FNA. In addition, thyroid scintigraphy may be useful in patients with multiple thyroid nodules to select those that are hypofunctional and therefore may require FNA. Although thyroid scintigraphy can be used to select nodules for FNA, it cannot be used to select patients for surgical resection.</p><p>Radionuclide scanning is contraindicated during pregnancy. If a woman is breastfeeding, breastfeeding should be suspended if a radionuclide scan is obtained. The amount of time will depend on which isotope is used (breastfeeding needs to be suspended longer if radioiodine is used). (See  <a class="medical medical_review" href="/d/html/7851.html" rel="external">"Overview of thyroid disease and pregnancy", section on 'Thyroid nodules'</a>.)</p><p>Scintigraphy utilizes one of the radioisotopes of iodine (usually 123-I) or technetium-99m pertechnetate. If available, radioiodine scanning is preferred. These radioisotopes are handled differently by thyroid follicular cells. Normal thyroid follicular cells take up both technetium and radioiodine, but only radioiodine is organified and stored (as thyroglobulin) in the lumen of thyroid follicles [<a href="#rid20">20</a>]. Most benign and virtually all malignant thyroid nodules concentrate both radioisotopes less avidly than adjacent normal thyroid tissue  (<a class="graphic graphic_diagnosticimage graphicRef68835" href="/d/graphic/68835.html" rel="external">image 1</a>). However, 5 percent of thyroid cancers concentrate pertechnetate but not radioiodine [<a href="#rid20">20</a>]. These nodules may appear hot or indeterminate ("warm") on pertechnetate scans and cold on radioiodine scans. Although most are benign nodules [<a href="#rid21">21-23</a>], a few are thyroid cancers [<a href="#rid22">22,24,25</a>]. As a result, patients with nodules that are functioning on pertechnetate imaging should undergo radioiodine imaging to confirm that they are actually functioning [<a href="#rid22">22,26</a>]. However, if the pertechnetate scan shows unequivocal increased uptake in a nodule with suppression of uptake elsewhere in the thyroid and an undetectable TSH, a radioiodine scan may not be necessary.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonfunctioning</strong> – Nonfunctioning nodules appear cold (uptake less than surrounding thyroid tissue)  (<a class="graphic graphic_diagnosticimage graphicRef68835" href="/d/graphic/68835.html" rel="external">image 1</a>), and they may require further evaluation by FNA. (See <a class="local">'Sonographic criteria for FNA'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autonomous</strong> – Autonomous nodules may appear hot (uptake is greater than surrounding thyroid tissue)  (<a class="graphic graphic_diagnosticimage graphicRef79487" href="/d/graphic/79487.html" rel="external">image 2</a>) if they are hyperfunctioning. Autonomous nodules that do not make sufficient thyroid hormone to suppress serum TSH concentrations will appear indeterminate on thyroid scintigraphy. Autonomous nodules account for only 5 to 10 percent of palpable nodules. Only a few patients with autonomous nodules have been found to have thyroid cancer [<a href="#rid27">27-29</a>], and only a few of these cancers were aggressive [<a href="#rid30">30</a>]. Furthermore, in some of these patients, the cancer was adjacent to the autonomous nodule rather than within it. Since hyperfunctioning nodules rarely are cancer, a nodule that is hyperfunctioning on radioiodine imaging does not require FNA. (See <a class="local">'Autonomous nodules'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indeterminate</strong> – Because scintigraphy is two dimensional, its limitations result from the superimposition of abnormal nodular tissue and normally functioning thyroid tissue  (<a class="graphic graphic_diagnosticimage graphicRef72057" href="/d/graphic/72057.html" rel="external">image 3</a>). Thus, while over 80 percent of nonautonomous nodules greater than 2 cm appear cold, smaller nodules present as a filling defect in less than one-third of cases [<a href="#rid27">27</a>]. The remaining majority of smaller nodules are indeterminate on thyroid scintigraphy [<a href="#rid31">31</a>]. They could represent either small, nonfunctioning nodules anterior or posterior to normally functioning thyroid tissue, or autonomous nodules that do not produce sufficient thyroid hormone to suppress TSH  (<a class="graphic graphic_diagnosticimage graphicRef51029" href="/d/graphic/51029.html" rel="external">image 4</a>).</p><p></p><p class="bulletIndent1">These indeterminate nodules should <strong>not</strong> be referred to as warm or functioning, since the majority are, in fact, nonfunctioning nodules. Indeterminate nodules on scintigraphy should be evaluated by FNA if they meet sonographic criteria for sampling. (See <a class="local">'Sonographic criteria for FNA'</a> below.)</p><p></p><p class="headingAnchor" id="H1584760"><span class="h3">TSH normal or high</span><span class="headingEndMark"> — </span>If the serum TSH concentration is normal or elevated and the nodule meets sonographic criteria for sampling  (<a class="graphic graphic_table graphicRef120691" href="/d/graphic/120691.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef70513" href="/d/graphic/70513.html" rel="external">table 4</a>), the next step in the evaluation of a thyroid nodule is an ultrasound-guided FNA biopsy; a palpation FNA biopsy may be performed if ultrasound is not available  (<a class="graphic graphic_algorithm graphicRef90862" href="/d/graphic/90862.html" rel="external">algorithm 1</a>). FNA biopsy is the most accurate method for evaluating thyroid nodules and identifying patients who require surgical resection [<a href="#rid7">7,32</a>]. FNA biopsy has resulted in improved diagnostic accuracy, a higher malignancy yield at the time of surgery, and significant cost reductions [<a href="#rid32">32-34</a>].</p><p>Nodules that do not meet sonographic criteria for FNA should be monitored. (See <a class="local">'Monitoring of nodules that do not meet FNA criteria'</a> below.)</p><p>Patients with a high serum TSH concentration require an evaluation for hypothyroidism. (See  <a class="medical medical_review" href="/d/html/7893.html" rel="external">"Diagnosis of and screening for hypothyroidism in nonpregnant adults"</a> and  <a class="medical medical_review" href="/d/html/7886.html" rel="external">"Disorders that cause hypothyroidism"</a>.)</p><p class="headingAnchor" id="H3997053873"><span class="h4">Fine-needle aspiration biopsy</span></p><p class="headingAnchor" id="H1586261"><span class="h5">Sonographic criteria for FNA</span><span class="headingEndMark"> — </span>Thyroid nodules are selected for FNA based on suspicious ultrasonographic characteristics rather than size alone, as the presence of suspicious ultrasound features is more predictive of malignancy [<a href="#rid10">10,35</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Decision analyses for selecting nodules for FNA</strong> – There are several approaches used to categorize thyroid nodules for likelihood of malignancy and to select nodules for biopsy. The American College of Radiology has proposed a system (Thyroid Imaging, Reporting and Data System [TIRADS]) for selecting nodules for FNA  (<a class="graphic graphic_table graphicRef120691" href="/d/graphic/120691.html" rel="external">table 3</a>) [<a href="#rid36">36</a>]. Similar, but not identical systems have been proposed in Europe, South Korea, and China (also called TIRADS) [<a href="#rid37">37-40</a>]. The ACR-TIRADS is more selective than the approach taken by the 2015 ATA guidelines  (<a class="graphic graphic_table graphicRef70513" href="/d/graphic/70513.html" rel="external">table 4</a>) [<a href="#rid7">7,41</a>]. It is also considerably more complex than the ATA criteria [<a href="#rid42">42</a>]. With TIRADS, suspicious sonographic features are assigned points, and the nodules are categorized as TR1 to 5 based on total points with increasing likelihood of malignancy. Category 3, 4, or 5 nodules are considered candidates for biopsy if the nodules are 25, 15, or 10 mm in size, respectively (<a class="calc calc_professional" href="/d/html/123056.html" rel="external">calculator 1</a>). These size cutoffs for FNA of thyroid nodules are higher for TR3 and TR4 nodules than those recommended by the ATA  (<a class="graphic graphic_table graphicRef70513" href="/d/graphic/70513.html" rel="external">table 4</a>) [<a href="#rid36">36,37</a>]. (See  <a class="medical medical_review" href="/d/html/7859.html" rel="external">"Overview of the clinical utility of ultrasonography in thyroid disease", section on 'Criteria for identifying cancer'</a>.)</p><p></p><p class="bulletIndent1">The various decision analyses differ in diagnostic performance and yield of FNA [<a href="#rid43">43-46</a>]. ACR-TIRADS reduces the number of biopsies done and improves accuracy [<a href="#rid44">44</a>]. In a meta-analysis of 12 studies and 18,750 nodules, it was superior to the approach taken by the 2015 ATA guidelines [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Our approach</strong> – Our approach is largely consistent with ACR-TIRADS  (<a class="graphic graphic_table graphicRef120691" data-inline-graphics="120691" href="/d/graphic/120691.html" rel="external">table 3</a>), but in anxious patients who are strongly motivated towards a biopsy, we may apply the less selective ATA guidelines  (<a class="graphic graphic_table graphicRef70513" data-inline-graphics="70513" href="/d/graphic/70513.html" rel="external">table 4</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Since active surveillance is considered safe for many papillary microcarcinomas, we generally do not biopsy highly suspicious (TR5) nodules under 10 mm  (<a class="graphic graphic_table graphicRef120691" href="/d/graphic/120691.html" rel="external">table 3</a>). However, since active surveillance is not recommended for papillary microcarcinoma with certain high-risk features, we consider FNA (if achievable) in any TR5 nodule (regardless of size) with these suspicious sonographic features:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Subcapsular locations adjacent to the recurrent laryngeal nerve (RLN) or trachea (the right RLN is located posterior and lateral to the right lobe, while the left RLN is posterior and medial)</p><p class="bulletIndent3"><span class="glyph">-</span>Extrathyroidal extension</p><p class="bulletIndent3"><span class="glyph">-</span>Extrusion through rim calcifications</p><p class="bulletIndent3"><span class="glyph">-</span>Associated with sonographically abnormal cervical lymph nodes</p><p></p><p class="bulletIndent2">Thyroid nodules under 5 mm are technically difficult to biopsy; before considering such a biopsy, the risk of a nondiagnostic result and the reliability of a negative result should be discussed with the patient. In the presence of abnormal cervical lymph nodes, FNA cytology may be obtained from the abnormal lymph node if the nodule is not amenable to FNA. (See  <a class="medical medical_review" href="/d/html/7889.html" rel="external">"Thyroid biopsy", section on 'Lymphadenopathy'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>FNA should be performed in nodules that are <strong>solid and hypoechoic</strong> if they are ≥1.5 cm (as determined by largest dimension). FNA should be performed in nodules that are solid and hypoechoic if they are ≥1 to 1.5 cm with one of these suspicious sonographic features:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Irregular margins (≥1.5 cm)</p><p class="bulletIndent3"><span class="glyph">-</span>Microcalcifications (≥1 cm)</p><p class="bulletIndent3"><span class="glyph">-</span>Taller-than-wide shape (≥1 cm)</p><p class="bulletIndent3"><span class="glyph">-</span>Macrocalcifications (≥1.5 cm)</p><p class="bulletIndent3"><span class="glyph">-</span>Peripheral (rim) calcifications (≥1.5 cm)</p><p class="bulletIndent3"><span class="glyph">-</span>Any combination (≥1 cm)</p><p></p><p class="bulletIndent2">The estimated risk of malignancy for hypoechoic solid nodules with one or more suspicious sonographic features is higher (35 to 90 percent) than for hypoechoic solid nodules without additional suspicious features (9 to 20 percent)  (<a class="graphic graphic_table graphicRef120691" href="/d/graphic/120691.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef70513" href="/d/graphic/70513.html" rel="external">table 4</a>). While the ATA also suggests ≥1 cm as their threshold for FNA in hypoechoic solid nodules without suspicious characteristics  (<a class="graphic graphic_table graphicRef70513" href="/d/graphic/70513.html" rel="external">table 4</a>), the American College of Radiology-Thyroid Imaging Reporting and Data System (ACR-TIRADS) use a threshold of ≥15 mm  (<a class="graphic graphic_table graphicRef120691" href="/d/graphic/120691.html" rel="external">table 3</a>). This decreases the number of benign and therefore unnecessary biopsies.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>FNA can be considered in selected patients with nodules &lt;1 cm if there is a strong family history of differentiated thyroid cancer (defined as at least two first-degree relatives), known syndromes associated with thyroid cancer, young age, a history of therapeutic childhood head and neck or whole-body radiation, or preference for FNA over observation. However, most patients with suspicious subcentimeter nodules can be observed [<a href="#rid47">47</a>]. Ideal candidates for observation of suspicious subcentimetric nodules include older patients (age &gt;60 years), especially those with comorbidities, with solitary nodules with well-defined margins and a &gt;2 mm rim of normal thyroid parenchyma; however, observation is also considered acceptable in all adult patients and those with multiple nodules. (See <a class="local">'Monitoring of nodules that do not meet FNA criteria'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nodules with sonographic appearance suggesting a low risk for thyroid cancer (isoechoic, hyperechoic, or partially cystic without suspicious characteristics in the solid component, estimated risk of malignancy 5 to 10 percent) can be biopsied when ≥2.5 cm  (<a class="graphic graphic_table graphicRef120691" href="/d/graphic/120691.html" rel="external">table 3</a>). These criteria apply to both palpable and nonpalpable nodules. This recommendation is based upon observational studies that show similar rates of cancer in nonpalpable nodules &gt;1 cm and palpable nodules of similar size [<a href="#rid9">9,11</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Spongiform nodules, defined as an aggregation of multiple microcystic components in more than 50 percent of the nodule volume, do not require FNA regardless of size (estimated risk of malignancy under 3 percent).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Purely cystic nodules (no mural component) do not require a biopsy.</p><p></p><p class="headingAnchor" id="H1585603"><span class="h5">FNA technique</span><span class="headingEndMark"> — </span>Tissue for histologic or cytologic examination may be obtained from the thyroid by several different techniques, including cutting needle biopsy, large- or fine-needle aspiration, or fine-needle capillary sampling. FNA biopsy is the most commonly used approach. A complete discussion of the techniques, their value and limitations, and potential complications can be found elsewhere. (See  <a class="medical medical_review" href="/d/html/7889.html" rel="external">"Thyroid biopsy"</a>.)</p><p>FNA is a simple and safe office procedure in which tissue samples are obtained for cytologic examination using 23- to 27- gauge (commonly 25-gauge) needles with or without local anesthesia. With experience, adequate samples can be obtained in 90 to 97 percent of aspirations of solid nodules.</p><p>Ultrasound-guided FNA biopsy should be performed for nonpalpable nodules and for nodules that are technically difficult to aspirate using palpation methods alone, such as predominantly cystic or posteriorly located nodules. In patients with large nodules (&gt;4 cm), ultrasound-guided FNA directed at several areas within the nodule may reduce the risk of a false-negative biopsy. (See  <a class="medical medical_review" href="/d/html/7889.html" rel="external">"Thyroid biopsy", section on 'Ultrasound guidance'</a> and  <a class="medical medical_review" href="/d/html/7850.html" rel="external">"Cystic thyroid nodules"</a>.)</p><p class="headingAnchor" id="H1586450"><span class="h5">Multiple nodules</span><span class="headingEndMark"> — </span>Patients with multiple nodules have the same risk of malignancy as those with a single nodule, although the risk of cancer in each individual nodule in a patient with multiple nodules is lower than the risk of cancer in a nodule in a patient with only one nodule [<a href="#rid19">19,35</a>]. Thus, the sonographic features of each nodule should be assessed independently to determine the need for FNA biopsy. If there are multiple coalescent nodules and none have suspicious sonographic features, FNA biopsy of the largest nodule is reasonable [<a href="#rid7">7</a>]. The nodules that are not biopsied should be monitored with periodic ultrasonography. (See <a class="local">'Monitoring of nodules that do not meet FNA criteria'</a> below.)</p><p class="headingAnchor" id="H1585697"><span class="h4">Monitoring of nodules that do not meet FNA criteria</span><span class="headingEndMark"> — </span>Nodules that do not meet sonographic criteria for FNA should be monitored. The frequency of evaluation depends upon the sonographic features of the nodules [<a href="#rid47">47</a>]. We perform periodic ultrasonography initially at:</p><p class="bulletIndent1"><span class="glyph">●</span>6 to 12 months for subcentimeter nodules with suspicious characteristics</p><p class="bulletIndent1"><span class="glyph">●</span>12 to 24 months for nodules with low to intermediate suspicion on ultrasound</p><p class="bulletIndent1"><span class="glyph">●</span>2 to 3 years for very-low-risk nodules</p><p></p><p>Subsequent ultrasounds can be obtained at increasing intervals over time, depending upon stability. Nodules that enlarge significantly should be assessed for FNA, and subcentimeter nodules that grow to ≥1 to 2.5 cm require a biopsy depending upon their size and ultrasound characteristics  (<a class="graphic graphic_table graphicRef120691" href="/d/graphic/120691.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef70513" href="/d/graphic/70513.html" rel="external">table 4</a>).</p><p>Evidence for an observational approach to subcentimeter nodules without suspicious ultrasound features comes from a prospective Italian study of the natural history of thyroid nodules, in which 992 patients (without apparent risk factors for thyroid cancer, but mild to moderately iodine deficient) with 1567 nodules were monitored with yearly thyroid ultrasound for five years [<a href="#rid48">48</a>]. During follow-up, only one cancer was diagnosed among the 852 subcentimeter thyroid nodules lacking high-risk ultrasound features. This nodule was biopsied due to the development of suspicious ultrasound features (hypoechogenicity, irregular margins), not growth. FNA biopsy was not performed on all of the nonsuspicious nodules, and therefore, this study cannot rule out the presence of asymptomatic, latent thyroid cancer. Additionally, the etiology and natural history of nodules in iodine-deficient regions may differ from that in iodine-sufficient regions such as the United States. Overall, however, the absence of suspicious ultrasound features on baseline examination is a reassuring finding in patients with subcentimeter nodules.</p><p class="headingAnchor" id="H15"><span class="h3">Serum calcitonin concentration</span><span class="headingEndMark"> — </span>The routine measurement of serum calcitonin in patients with nodular thyroid disease is controversial [<a href="#rid49">49-51</a>]. At present, we agree with others that the routine use of basal calcitonin measurements in nodular thyroid disease is not warranted in countries (eg, United States, Canada) where the use of pentagastrin stimulation as a confirmatory test is not available [<a href="#rid52">52,53</a>]. If pentagastrin stimulation testing were available, some thyroid experts would routinely measure serum calcitonin in patients with nodular thyroid disease, whereas others would not [<a href="#rid49">49-51,54</a>]. The ATA notes the uncertainties surrounding calcitonin measurements and has not taken a position for or against calcitonin screening [<a href="#rid7">7,55</a>].</p><p>If the basal serum calcitonin level is measured and exceeds 10 pg/mL, the calcitonin measurement should be repeated after pentagastrin stimulation testing (after renal insufficiency and use of proton pump inhibitor medication have been ruled out) [<a href="#rid56">56</a>]. Calcium is also a calcitonin secretagogue; owing to the unavailability of pentagastrin in many countries, there is a growing interest in using the calcium stimulation test as a confirmatory test in patients with elevated basal calcitonin levels. However, few standardized data using modern calcitonin assays are available [<a href="#rid57">57,58</a>]. Pentagastrin and calcium stimulation testing are reviewed separately. (See  <a class="medical medical_review" href="/d/html/7870.html" rel="external">"Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2", section on 'Biochemical testing'</a>.)</p><p>Several reports have suggested that serum calcitonin should be measured routinely in patients with nodular thyroid disease in order to identify those who have medullary thyroid cancer (MTC) at an earlier stage and to improve survival [<a href="#rid59">59-70</a>] . However, controversy remains about the routine use of serum calcitonin measurements because of the absence of uniform calcitonin thresholds to distinguish sporadic occult MTC [<a href="#rid64">64,71-73</a>], the high false-positive rate (59 percent or higher) in some studies, and the uncertain importance of small tumors [<a href="#rid32">32,74</a>]. (See  <a class="medical medical_review" href="/d/html/7848.html" rel="external">"Medullary thyroid cancer: Clinical manifestations, diagnosis, and staging"</a> and  <a class="medical medical_review" href="/d/html/7870.html" rel="external">"Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2", section on 'Medullary thyroid cancer'</a>.)</p><p>Data on the utility of routine serum calcitonin measurement in patients with nodular thyroid disease are largely from prospective cohort studies . In various reports, basal serum calcitonin was increased in 0.5 to 5 percent of patients with thyroid nodules [<a href="#rid63">63,66,69</a>]. In a study of 1167 French patients with nodular thyroid disease, the prevalence of MTC in patients with elevated versus normal basal calcitonin levels was 41.1 and 0.17 percent, respectively [<a href="#rid60">60</a>].</p><p>In the studies that showed a diagnostic advantage to measuring basal serum calcitonin [<a href="#rid56">56,60,63,70</a>], however, serum calcitonin was repeated after pentagastrin (available only in some countries) stimulation to confirm MTC or C cell hyperplasia in those with elevated calcitonin levels. As an example, in one report of 10,864 patients screened after 1991, 44 (0.4 percent) had an elevated calcitonin, all confirmed by an elevated pentagastrin-stimulated calcitonin, and all had MTC [<a href="#rid63">63</a>]. Fifty-nine percent of these patients were in complete remission compared with only 2.7 percent of patients diagnosed with MTC prior to the use of routine screening, suggesting a benefit to early diagnosis. In contrast, in a study of 10,158 patients with thyroid nodules, 5 percent had elevated basal calcitonin, but only 20 percent of these patients had elevated values after pentagastrin stimulation and only 31 percent of these patients had MTC [<a href="#rid66">66</a>]. In all of these studies, calcitonin was more accurate than FNA for identifying MTC since many of the cancers were quite small. In the French study, only 2 of 12 patients diagnosed by calcitonin measurement had lesions that were 1 cm in diameter or larger, while four were less than 0.3 cm in diameter [<a href="#rid60">60</a>].</p><p>False-positive calcitonin results may be obtained in patients with hypercalcemia, hypergastrinemia, neuroendocrine tumors, renal insufficiency, papillary and follicular thyroid carcinomas, goiter, and chronic autoimmune thyroiditis [<a href="#rid32">32,75</a>]. Furthermore, prolonged treatment with <a class="drug drug_general" data-topicid="9718" href="/d/drug information/9718.html" rel="external">omeprazole</a> (greater than two to four months), beta blockers, and glucocorticoids have been associated with hypercalcitoninemia [<a href="#rid76">76</a>]. In addition, there are reports of rare MTCs that do not secrete calcitonin, and a false-negative test result may be expected [<a href="#rid77">77,78</a>].</p><p class="headingAnchor" id="H16"><span class="h3">Other laboratory tests</span><span class="headingEndMark"> — </span>Routine measurement of serum antithyroid peroxidase (TPO) antibodies and thyroglobulin is not necessary.</p><p>Measurement of TPO antibodies may be helpful in patients with a high TSH suggestive of chronic autoimmune (Hashimoto's) thyroiditis. However, the presence of a high titer of TPO antibodies does not negate the need for FNA biopsy of a thyroid nodule in a patient with Hashimoto's thyroiditis. In a prospective study of 14,063 FNAs, the risk of malignancy was 23 percent in patients with coexisting Hashimoto's thyroiditis and 16 percent in those without thyroiditis [<a href="#rid79">79</a>]. Rapid shrinkage of the nodule when T4 (<a class="drug drug_general" data-topicid="9557" href="/d/drug information/9557.html" rel="external">levothyroxine</a>) therapy is instituted may be sufficiently reassuring to mitigate further concern. However, thyroiditis and thyroid cancer may coexist, particularly after head and neck irradiation [<a href="#rid67">67,80</a>]. Thus, a definite nodule, even in the presence of a high serum antibody concentration, requires further evaluation.</p><p>Serum thyroglobulin levels can be elevated in many thyroid diseases including benign goiter, hyperthyroidism, and any cause of a destructive thyroiditis. An elevated level does not help discriminate benign from malignant thyroid nodules. Thus, we do not measure serum thyroglobulin levels as part of the evaluation of patients with a thyroid nodule.</p><p class="headingAnchor" id="H17"><span class="h2">Thyroid incidentalomas</span><span class="headingEndMark"> — </span>Incidentalomas are nonpalpable thyroid nodules that are detected during other imaging procedures. Nonpalpable nodules have approximately the same risk of malignancy as palpable nodules [<a href="#rid8">8-11</a>]. In some settings, especially nodules discovered on PET scan (see <a class="local">'PET scans'</a> below), the risk of malignancy may be higher, but in other settings (cystic nodules), it is lower.</p><p class="headingAnchor" id="H18"><span class="h3">Patients with a history of childhood head or neck irradiation</span><span class="headingEndMark"> — </span>Radiation exposure of the thyroid during childhood is the most clearly defined environmental factor associated with benign and malignant thyroid tumors. There is a linear dose-response curve, with no evidence of a threshold at low doses. The risk reaches a plateau and possibly tapers off at high doses. (See  <a class="medical medical_review" href="/d/html/7059.html" rel="external">"Radiation-induced thyroid disease"</a>.)</p><p>Many patients with a history of radiation exposure during childhood have nonpalpable thyroid nodules. This was illustrated by a report in which 54 such patients underwent thyroid ultrasonography [<a href="#rid81">81</a>]. Although most of the patients had no palpable nodules, 47 had 157 nodules on ultrasonography. The nodules ranged in size from a few millimeters to 3 cm. Eleven nodules were 1.5 cm or larger, six of which could be palpated.</p><p>The arguments for and against the routine use of ultrasonographic screening in patients with a history of radiation are reviewed in detail elsewhere. We recommend ultrasonography based upon an assessment of each patient's risk factors for thyroid cancer. (See  <a class="medical medical_review" href="/d/html/7059.html" rel="external">"Radiation-induced thyroid disease", section on 'Surveillance for structural thyroid abnormalities'</a>.)</p><p class="headingAnchor" id="H20"><span class="h3">PET scans</span><span class="headingEndMark"> — </span>Thyroid nodules ≥1 cm with focal FDG uptake that are discovered incidentally on PET scans require ultrasound-guided FNA biopsy  (<a class="graphic graphic_diagnosticimage graphicRef93365" href="/d/graphic/93365.html" rel="external">image 5</a>) [<a href="#rid7">7</a>]. However, if there is focal FDG uptake and the TSH is low, a radioiodine scan should be obtained to determine if the nodule is functional (autonomous) (see <a class="local">'Thyroid scintigraphy'</a> above). If the nodule is autonomous, it is unlikely to be malignant; however, there is insufficient evidence to be certain. While it is likely that FNA is not needed for these patients, the optimal approach is unclear, and obtaining an FNA is a reasonable approach in light of this uncertainty.</p><p>Many incidentalomas found on PET scans are thyroid cancers (differentiated thyroid cancer or MTC) [<a href="#rid82">82-84</a>]. In a systematic review of 22 studies evaluating incidentally found hypermetabolic activity in the thyroid gland by PET scan (1994 patients with unexpected focal hypermetabolic activity, 999 with unexpected diffuse activity), a diagnosis was assigned in 1051 and 168 patients, respectively [<a href="#rid85">85</a>]. Among those with a focal FDG uptake, 366 of 1051 (34.8 percent) had a thyroid malignancy compared with 7 of 168 patients (4.4 percent) with diffuse uptake. The mean maximum standardized uptake value (SUVmax) was 6.9 and 4.8 in malignant and benign lesions, respectively.</p><p>In a small, retrospective study of follicular neoplasms that had PET scans within a year of FNA and had surgical excision of the nodule, 1 of 19 (5 percent) FDG negative (&lt;5 SUV) and 4 of 26 (15 percent) FDG positive (&gt;5 SUV) were malignant [<a href="#rid86">86</a>].</p><p>Of note, Hashimoto's thyroiditis is often FDG avid with diffuse activity. As a result, if the patient has Hashimoto's thyroiditis, the PET images should be carefully reviewed to determine if the FDG uptake is truly focal and consistent with a nodule, rather than representing uptake by the entire gland.</p><p class="headingAnchor" id="H21"><span class="h3">Graves' disease</span><span class="headingEndMark"> — </span>The prevalence of thyroid nodules and cancer in patients with Graves' disease has been investigated in a prospective study in which 245 patients with Graves' underwent screening ultrasonography. Thirty-five percent had nodules, and 3.3 percent had thyroid cancers (one of eight cancers was palpable) [<a href="#rid87">87</a>]. The risk of malignancy was higher in patients over age 45 years. We limit ultrasonography to Graves' patients with palpable abnormalities or heterogeneous or focal decreased uptake on thyroid scintigraphy. Ultimately, the decision to FNA is dependent upon ultrasound characteristics, rather than findings on thyroid scintigraphy, as it may be difficult to determine if a nodule is functional on scintigraphy since the nodule is surrounded by hyperactive thyroid tissue.</p><p class="headingAnchor" id="H22"><span class="h3">Cystic nodules</span><span class="headingEndMark"> — </span>The majority of cystic thyroid nodules are benign, degenerating thyroid adenomas. However, thyroid cancers may be cystic. The presence of suspicious ultrasound features in mural tissue in the cystic nodule is more predictive of malignancy than nodule size alone. The decision to biopsy a thyroid nodule should be based upon a combination of ultrasonographic features of the solid component and nodule size  (<a class="graphic graphic_table graphicRef120691" href="/d/graphic/120691.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef70513" href="/d/graphic/70513.html" rel="external">table 4</a>). The evaluation and management of cystic nodules are reviewed in more detail elsewhere. (See  <a class="medical medical_review" href="/d/html/7850.html" rel="external">"Cystic thyroid nodules"</a>.)</p><p class="headingAnchor" id="H23"><span class="h2">Pregnancy</span><span class="headingEndMark"> — </span>Thyroid radionuclide scanning is contraindicated during pregnancy. Otherwise, a pregnant woman found to have a thyroid nodule can be evaluated in the same way as if she were not pregnant. (See  <a class="medical medical_review" href="/d/html/7851.html" rel="external">"Overview of thyroid disease and pregnancy", section on 'Thyroid nodules'</a>.)</p><p class="headingAnchor" id="H24"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>The optimal therapy for patients with thyroid nodules varies with the lesion that is found and whether or not it is functioning.</p><p class="headingAnchor" id="H1083396"><span class="h2">FNA cytology</span><span class="headingEndMark"> — </span>There are six major categories of results that are obtained from fine-needle aspiration (FNA), each of which indicates different subsequent management. The diagnostic categories (Bethesda classification)  (<a class="graphic graphic_table graphicRef106281" href="/d/graphic/106281.html" rel="external">table 5</a>) and cytopathologic diagnoses of FNA results are reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/7889.html" rel="external">"Thyroid biopsy", section on 'Diagnostic categories'</a> and  <a class="medical medical_review" href="/d/html/7823.html" rel="external">"Atlas of thyroid cytopathology"</a>.)</p><p class="headingAnchor" id="H25"><span class="h3">Benign nodules (Bethesda II)</span></p><p class="headingAnchor" id="H430937246"><span class="h4">Surveillance</span><span class="headingEndMark"> — </span>Patients with benign nodules (macrofollicular or adenomatoid/hyperplastic nodules, colloid adenomas, nodular goiter, and Hashimoto's thyroiditis) are usually monitored without treatment. In the absence of a history of childhood neck irradiation, patients with benign nodules should not be treated with T4. (See  <a class="medical medical_review" href="/d/html/7887.html" rel="external">"Thyroid hormone suppressive therapy for thyroid nodules and benign goiter"</a>.)</p><p>We perform periodic ultrasound monitoring of benign thyroid nodules, initially at 12 to 24 months, then at increasing intervals over time (eg, three to five years), with the shorter intervals for large nodules or nodules with worrisome ultrasound features and the longer interval for smaller nodules with classic benign ultrasonographic features. We repeat the FNA within 12 months if the nodule has highly suspicious ultrasound features despite a benign biopsy.</p><p>Small changes in nodule size on serial ultrasonography do not require a repeat aspiration. However, reassessment is warranted when there is any of the following [<a href="#rid7">7,48</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Substantial growth (more than a 50 percent change in volume or 20 percent increase in nodule diameter with a minimum increase in two or more dimensions of at least 2 mm)</p><p class="bulletIndent1"><span class="glyph">●</span>Appearance of suspicious ultrasound features</p><p class="bulletIndent1"><span class="glyph">●</span>New symptoms are attributed to a nodule</p><p></p><p>If a nodule is re-aspirated and the second cytology is benign, ultrasound assessment of this particular nodule for possible risk of malignancy is no longer necessary [<a href="#rid7">7,88</a>]. If the second cytology is abnormal, treatment is based on the specific findings. (See  <a class="medical medical_review" href="/d/html/116428.html" rel="external">"Evaluation and management of thyroid nodules with indeterminate cytology in adults"</a> and <a class="local">'Suspicious for malignancy (Bethesda V)'</a> below and <a class="local">'Malignant (Bethesda VI)'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rationale for monitoring</strong> – The purpose of monitoring is to identify nodular growth, potentially indicating a falsely benign nodule. However, the false-negative rate of a benign interpretation is low (0 to 10 percent) [<a href="#rid48">48,89-91</a>]. Re-aspiration of thyroid nodules that are unchanged clinically is not warranted, because detection of malignancy is uncommon in routine repeat biopsies [<a href="#rid92">92-96</a>]. This was illustrated in two studies of 250 patients who had routine repeat FNA; only one previously benign nodule was found to be malignant on repeat aspiration (0.4 percent) [<a href="#rid92">92,93</a>]. In a third report, 3 of 216 patients (1.4 percent) had papillary cancer on a repeat biopsy [<a href="#rid95">95</a>].</p><p></p><p class="bulletIndent1">Malignancy is rare even in benign thyroid nodules that have grown [<a href="#rid48">48,97,98</a>]. Cystic degeneration and hemorrhage are the most common causes of sudden enlargement and can be detected by ultrasonography or repeat aspiration [<a href="#rid31">31</a>]. In a prospective Italian study of the natural history of thyroid nodules, 992 mild to moderately iodine-deficient patients (without apparent risk factors for thyroid cancer) with 1567 nodules were monitored with yearly thyroid ultrasound for five years [<a href="#rid48">48</a>]. Nodular growth and nodule shrinkage occurred in 15.4 and 18.5 percent of patients, respectively. Among the 630 nodules (40.2 percent) that were classified as benign based on cytologic findings, only four nodules were subsequently found to be papillary thyroid cancer. Two of the four nodules were re-aspirated due to growth. However, the remaining two nodules were re-aspirated because of the appearance of suspicious ultrasound features, not growth.</p><p></p><p class="bulletIndent1">A retrospective study assessed the growth rate of 126 malignant thyroid nodules followed for at least six months (mean 21 months) prior to surgery compared with 1363 benign nodules and found that 26 percent of malignant and 12 percent of benign nodules grew by more than 2 mm per year, with the relative risk (RR) of malignancy increasing from 1.85 to 5.05 for growth rates of more than 2 mm to more than 8 mm per year, respectively [<a href="#rid99">99</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Frequency of ultrasound imaging</strong> – The appropriate interval for ultrasound monitoring is uncertain as there are few studies that examine this issue. In a retrospective cohort study of 1369 patients with 2010 cytologically benign nodules, followed for an average of 8.5 years, there were no deaths attributable to thyroid illness or thyroid cancer [<a href="#rid100">100</a>]. Among the 325 patients who subsequently underwent thyroidectomy despite initially benign cytology, 45 (14 percent) had surgery because of abnormal cytology obtained on a repeat FNA biopsy of the same nodule (performed because of growth). Eighteen false-negative FNA results (1.3 percent) were confirmed (16 papillary, one follicular, one poorly differentiated cancer), and the mean time from initial benign cytology to thyroidectomy in these patients was 4.5 years. None of the patients had distant metastatic disease, and all were alive with no recurrence over a mean follow-up period of 11 years. This study, along with the prospective Italian study [<a href="#rid48">48</a>], suggests that less frequent monitoring of cytologically benign nodules may be warranted.</p><p></p><p class="headingAnchor" id="H3929756485"><span class="h4">Symptomatic benign nodules</span><span class="headingEndMark"> — </span>For symptomatic or cosmetically concerning benign nodules, we suggest surgery (typically lobectomy). Where expertise is available, ultrasound-guided ablation techniques are an alternative.  </p><p>Surgery has been the preferred treatment for symptomatic benign nodules. It is effective, but it is expensive and may be associated with complications. Surgical complications are lower when surgery is performed by surgeons with expertise in thyroid surgery [<a href="#rid101">101</a>] and when the extent of resection is limited (lobectomy versus total thyroidectomy). (See  <a class="medical medical_review" href="/d/html/2157.html" rel="external">"Thyroidectomy", section on 'Complications'</a>.) </p><p>Benign nodules can also be treated by ultrasound-directed physical energy (eg, radiofrequency ablation, laser ablation, microwave ablation, high-intensity focused ultrasound). While these approaches are utilized in Europe and Asia, they have not previously gained widespread acceptance in the United States. However, expertise in these techniques is developing, and many academic centers have set up programs for radiofrequency ablation of benign nodules (confirmed by two benign FNA results or one benign FNA result and a spongiform or predominantly cystic appearance on ultrasound) [<a href="#rid102">102,103</a>].</p><p>In a systematic review and network meta-analysis of 16 studies (3 randomized trials and 13 comparative case series) evaluating thermal ablation techniques or conventional surgery to treat benign thyroid nodules, thyroidectomy was associated with the largest reduction in thyroid volume compared with thermal ablation techniques but a higher risk of postoperative complications (eg, laryngeal nerve damage) and hypothyroidism [<a href="#rid104">104</a>]. There was no difference among the thermal ablation techniques in volume reduction, symptom score, or cosmetic score. The relatively short-term follow-up (mean 11.9 months) limited the evaluation of recurrent nodules. There were no trials comparing thyroid lobectomy with any thermal ablation technique.</p><p>In prospective studies, ultrasound-guided ablative procedures for benign, symptomatic nodules reduce volume size (mean reduction at six months 67 to 86 percent) and improve thyroid specific quality-of-life scores [<a href="#rid105">105-107</a>]. Adverse effects may include pain during and after the procedure and hematoma. Recurrent laryngeal nerve damage (often transient), skin burns, and tracheal injury have also been reported [<a href="#rid107">107,108</a>]. Treatment efficacy improves as clinicians increase their proficiency with the procedures. In one study, the efficacy of radiofrequency ablation (as assessed by the volume reduction ratio and ablation ratio) improved for cases 31 to 60 compared with the first 30 cases; further improvement in ablation ratio for smaller nodules was noted for cases 61 to 90 compared with cases 31 to 60, suggesting the learning curve continues beyond the first 60 cases [<a href="#rid109">109</a>].</p><p class="headingAnchor" id="H15571226"><span class="h3">Indeterminate cytology (Bethesda III and IV)</span><span class="headingEndMark"> — </span>When cytologic results show atypia of undetermined significance (AUS) or follicular neoplasm, the results are often called indeterminate. The evaluation and management of nodules with indeterminate cytology, including the application of molecular markers, is reviewed separately. (See  <a class="medical medical_review" href="/d/html/116428.html" rel="external">"Evaluation and management of thyroid nodules with indeterminate cytology in adults"</a>.)</p><p class="headingAnchor" id="H28"><span class="h3">Suspicious for malignancy (Bethesda V)</span><span class="headingEndMark"> — </span>This category includes lesions with some features suggestive of, but not definitive for, papillary thyroid cancer, or other malignancies. Typically, nodules in this category have a 67 to 83 percent risk of malignancy or noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP, formerly called noninvasive follicular variant of papillary thyroid cancer but subsequently reclassified as a benign variant) (see  <a class="medical medical_review" href="/d/html/7860.html" rel="external">"Papillary thyroid cancer: Clinical features and prognosis", section on 'Variant forms'</a>) [<a href="#rid91">91</a>]. Such patients should be referred for surgery. Molecular markers should not be used for this category; however, the results of mutational analysis may be helpful when the choice between lobectomy and total thyroidectomy is uncertain. (See  <a class="medical medical_review" href="/d/html/116428.html" rel="external">"Evaluation and management of thyroid nodules with indeterminate cytology in adults", section on 'Molecular markers'</a>.)</p><p class="headingAnchor" id="H29"><span class="h3">Malignant (Bethesda VI)</span><span class="headingEndMark"> — </span>The malignant category includes papillary cancer, medullary thyroid cancer (MTC), thyroid lymphoma, anaplastic cancer, and cancer metastatic to the thyroid. Patients with cytology diagnostic of malignancy should be referred for surgery. (See  <a class="medical medical_review" href="/d/html/7821.html" rel="external">"Differentiated thyroid cancer: Surgical treatment"</a>.)</p><p>For biopsy-proven papillary microcarcinoma confined to the thyroid with no cervical nodes or high-grade features, active surveillance is an alternative to surgery, especially for patients with other comorbidities who are at increased surgical risk [<a href="#rid47">47,110,111</a>]. However, if the recommendations for FNA noted above are followed, the preoperative diagnosis of papillary microcarcinoma should be a rare event. (See <a class="local">'Sonographic criteria for FNA'</a> above.)</p><p class="headingAnchor" id="H30"><span class="h3">Nondiagnostic (Bethesda I)</span><span class="headingEndMark"> — </span>A nondiagnostic biopsy is cytologically inadequate. It is critical that the absence of malignant cells not be interpreted as a negative biopsy if no or scant follicular tissue is obtained. For patients with nondiagnostic FNA biopsies, we repeat the FNA in approximately four to six weeks, using ultrasound guidance if not used for the first FNA. In a study of patients with a nondiagnostic cytology specimen after a palpation FNA, repeating the FNA under ultrasound guidance significantly improved the diagnostic yield for both solid and cystic nodules [<a href="#rid112">112</a>].</p><p>If repeated ultrasound-guided aspirations are nondiagnostic, ultrasound-guided core-needle biopsy should be considered. In one study of patients who had one nondiagnostic FNA, a core-needle biopsy provided diagnostic results in 74 percent of patients, while a repeat FNA provided a result in only 52 percent of patients; after two nondiagnostic FNAs, the core needle provided a result in 86 versus 29 percent for FNA [<a href="#rid113">113</a>].</p><p>Surgical excision, especially for larger, solid nodules with sonographically suspicious features  (<a class="graphic graphic_table graphicRef68199" href="/d/graphic/68199.html" rel="external">table 2</a>) [<a href="#rid114">114</a>], or observation, especially for smaller, partially cystic nodules, are reasonable options for repeatedly nondiagnostic biopsies. If growth of the solid component of the nodule (&gt;20 percent in two dimensions on ultrasound) is detected during observation, diagnostic surgery is also reasonable.</p><p>In a study of 2234 consecutive FNAs, 352 (16 percent) were nondiagnostic. Among nondiagnostic nodules, 42 percent were nondiagnostic on a second FNA and 68 percent on a third FNA attempt. While not all nondiagnostic nodules were excised, papillary thyroid cancer was diagnosed in 8 percent [<a href="#rid115">115</a>].</p><p class="headingAnchor" id="H31"><span class="h2">Autonomous nodules</span><span class="headingEndMark"> — </span>The optimal therapy of patients with autonomous nodules is controversial. Those in whom the nodule causes hyperthyroidism should be treated with radioiodine, surgery, or long-term antithyroid drugs. For patients who prefer to avoid radioiodine or surgery, ultrasound-guided thermal ablation procedures are an option (if centers with expertise are available). (See  <a class="medical medical_review" href="/d/html/7873.html" rel="external">"Treatment of toxic adenoma and toxic multinodular goiter"</a>.)</p><p>Patients with subclinical hyperthyroidism (low serum TSH and normal serum free thyroxine [T4] values) present a difficult problem. Subclinical hyperthyroidism is associated with an increased risk of atrial fibrillation in patients over age 60 to 65 years and, in postmenopausal women, a decrease in bone mineral density (BMD). Management depends upon clinical risk for complications of subclinical hyperthyroidism and the degree of TSH suppression. This topic is reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/7881.html" rel="external">"Subclinical hyperthyroidism in nonpregnant adults"</a>.)</p><p class="headingAnchor" id="H32"><span class="h2">Cystic thyroid nodules</span><span class="headingEndMark"> — </span>Cystic nodules also present difficult management issues. Many patients with small cystic nodules with nondiagnostic cytology can be followed with the assumption that the nodule is benign. In some patients, however, recurrent bleeding or cyst reformation may be a source of discomfort, anxiety, or rarely obstructive symptoms. Management is reviewed in more detail separately. (See  <a class="medical medical_review" href="/d/html/7850.html" rel="external">"Cystic thyroid nodules", section on 'Management'</a>.)</p><p class="headingAnchor" id="H2803189062"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/113808.html" rel="external">"Society guideline links: Thyroid nodules and cancer"</a>.)</p><p class="headingAnchor" id="H34"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15901.html" rel="external">"Patient education: Thyroid nodules (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/17222.html" rel="external">"Patient education: Nodular goiter (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/2162.html" rel="external">"Patient education: Thyroid nodules (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H35"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial evaluation</strong> – The initial evaluation in all patients with a thyroid nodule (discovered either by palpation or incidentally noted on a radiologic procedure, such as carotid ultrasonography, neck or chest computed tomography [CT], or positron emission tomography [PET]) includes a history, physical examination, neck ultrasonography, and measurement of serum thyroid-stimulating hormone (TSH)  (<a class="graphic graphic_algorithm graphicRef90862" href="/d/graphic/90862.html" rel="external">algorithm 1</a>). (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>TSH low</strong> – Thyroid scintigraphy should be performed in patients with a subnormal serum TSH concentration. (See <a class="local">'TSH low'</a> above and <a class="local">'Thyroid scintigraphy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>TSH normal or elevated</strong> – If the serum TSH concentration is normal or elevated and the nodule meets sonographic criteria for sampling  (<a class="graphic graphic_table graphicRef120691" href="/d/graphic/120691.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef70513" href="/d/graphic/70513.html" rel="external">table 4</a>), ultrasound-guided fine-needle aspiration (FNA) biopsy should be performed; a palpation FNA biopsy may be performed if ultrasound is not available  (<a class="graphic graphic_algorithm graphicRef90862" href="/d/graphic/90862.html" rel="external">algorithm 1</a>). FNA biopsy is the most accurate method for evaluating thyroid nodules and selecting patients for thyroid surgery. Nodules that do not meet sonographic criteria for FNA should be monitored. The frequency of evaluation depends upon the sonographic features of the nodules. (See <a class="local">'TSH normal or high'</a> above and <a class="local">'Monitoring of nodules that do not meet FNA criteria'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sonographic criteria for FNA</strong> – Thyroid nodules are selected for FNA based on suspicious ultrasonographic characteristics rather than size alone, as the presence of suspicious ultrasound features is more predictive of malignancy. (See <a class="local">'Sonographic criteria for FNA'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Since active surveillance is considered safe for many papillary microcarcinomas, we generally do not biopsy highly suspicious (TR5) nodules under 10 mm. However, since active surveillance is not recommended for papillary microcarcinoma with certain high-risk features, we consider FNA (if achievable) in any TR5 nodule (regardless of size) with these suspicious sonographic features: subcapsular locations adjacent to the recurrent laryngeal nerve or trachea, extrathyroidal extension, extrusion through rim calcifications, or associated with abnormal lymph nodes.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>FNA should be performed in nodules that are <strong>solid and hypoechoic</strong> if they are ≥1.5 cm (as determined by largest dimension). FNA should be performed in nodules that are solid and hypoechoic if they are ≥1 to 1.5 cm with one of these suspicious sonographic features: irregular margins (≥1.5 cm), microcalcifications (≥1 cm), taller-than-wide shape (≥1 cm), macrocalcifications (≥1.5 cm), peripheral (rim) calcifications (≥1.5 cm).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nodules with sonographic appearance suggesting a low risk for thyroid cancer can be biopsied when larger (≥2.5 cm)  (<a class="graphic graphic_table graphicRef120691" href="/d/graphic/120691.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef70513" href="/d/graphic/70513.html" rel="external">table 4</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Spongiform nodules can be observed without FNA.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>FNA technique</strong> – FNA biopsy of thyroid nodules is most commonly performed under ultrasound guidance. Ultrasound-guided FNA biopsy should always be performed for nonpalpable nodules and for nodules that are technically difficult to aspirate using palpation methods alone, such as predominantly cystic or posteriorly located nodules. In patients with large nodules (&gt;4 cm), ultrasound-guided FNA directed at several areas within the nodule may reduce the risk of a false-negative biopsy. (See <a class="local">'FNA technique'</a> above and  <a class="medical medical_review" href="/d/html/7889.html" rel="external">"Thyroid biopsy", section on 'Ultrasound guidance'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Benign cytology</strong> – Patients with benign nodules (macrofollicular or adenomatoid/hyperplastic nodules, colloid adenomas, nodular goiter, and Hashimoto's thyroiditis) are usually followed without treatment. (See <a class="local">'Surveillance'</a> above.)</p><p></p><p class="bulletIndent2">We perform periodic ultrasound monitoring of benign thyroid nodules initially at 12 to 24 months, then at increasing intervals (eg, three to five years), with the shorter intervals for large nodules or nodules with worrisome ultrasound features and the longer interval for smaller nodules with classic benign ultrasonographic features.</p><p></p><p class="bulletIndent2">We repeat the FNA within 12 months if the initial ultrasound shows highly suspicious ultrasound features despite a benign biopsy. Repeat FNA is also warranted when there is substantial growth (more than a 50 percent change in volume or 20 percent increase in at least two nodule dimensions), there is the appearance of suspicious ultrasound features, or new symptoms are attributed to a nodule.</p><p></p><p class="bulletIndent2">For symptomatic or cosmetically concerning benign nodules, we suggest surgery (typically lobectomy) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Where expertise is available, ultrasound-guided ablation techniques are an alternative. (See <a class="local">'Symptomatic benign nodules'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Indeterminate cytology</strong> – The evaluation and management of nodules with indeterminate cytology (atypia of undetermined significance [AUS] or follicular neoplasm), including the application of molecular markers, is reviewed separately. (See  <a class="medical medical_review" href="/d/html/116428.html" rel="external">"Evaluation and management of thyroid nodules with indeterminate cytology in adults"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Suspicious for malignancy or malignant</strong> – Patients with nodules that are suspicious for malignancy or malignant should be referred for surgery. (See <a class="local">'Suspicious for malignancy (Bethesda V)'</a> above and <a class="local">'Malignant (Bethesda VI)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nondiagnostic cytology</strong> – For patients with nondiagnostic palpation or ultrasound-guided biopsies, we perform repeat FNA using ultrasound guidance. For patients with<strong> </strong>solid nodules and nondiagnostic cytology after repeated biopsies, we typically perform an ultrasound-guided core-needle biopsy. Careful clinical follow-up, repeat FNA biopsy, and surgical resection are alternative options. For cytologically nondiagnostic nodules that are predominately cystic, we suggest careful clinical follow-up with ultrasound monitoring rather than surgical resection (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Nondiagnostic (Bethesda I)'</a> above and  <a class="medical medical_review" href="/d/html/7850.html" rel="external">"Cystic thyroid nodules"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Werk EE Jr, Vernon BM, Gonzalez JJ, et al. Cancer in thyroid nodules. A community hospital survey. Arch Intern Med 1984; 144:474.</a></li><li><a class="nounderline abstract_t">Belfiore A, Giuffrida D, La Rosa GL, et al. High frequency of cancer in cold thyroid nodules occurring at young age. Acta Endocrinol (Copenh) 1989; 121:197.</a></li><li><a class="nounderline abstract_t">Hegedüs L. Clinical practice. The thyroid nodule. N Engl J Med 2004; 351:1764.</a></li><li><a class="nounderline abstract_t">Lin JD, Chao TC, Huang BY, et al. Thyroid cancer in the thyroid nodules evaluated by ultrasonography and fine-needle aspiration cytology. Thyroid 2005; 15:708.</a></li><li><a class="nounderline abstract_t">Kwong N, Medici M, Angell TE, et al. The Influence of Patient Age on Thyroid Nodule Formation, Multinodularity, and Thyroid Cancer Risk. J Clin Endocrinol Metab 2015; 100:4434.</a></li><li class="breakAll">National Comprehensive Cancer Network http://www.nccn.org/professionals/physician_gls/f_guidelines.asp (Accessed on July 11, 2013).</li><li><a class="nounderline abstract_t">Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016; 26:1.</a></li><li><a class="nounderline abstract_t">Steele SR, Martin MJ, Mullenix PS, et al. The significance of incidental thyroid abnormalities identified during carotid duplex ultrasonography. Arch Surg 2005; 140:981.</a></li><li><a class="nounderline abstract_t">Hagag P, Strauss S, Weiss M. Role of ultrasound-guided fine-needle aspiration biopsy in evaluation of nonpalpable thyroid nodules. Thyroid 1998; 8:989.</a></li><li><a class="nounderline abstract_t">Leenhardt L, Hejblum G, Franc B, et al. Indications and limits of ultrasound-guided cytology in the management of nonpalpable thyroid nodules. J Clin Endocrinol Metab 1999; 84:24.</a></li><li><a class="nounderline abstract_t">Nam-Goong IS, Kim HY, Gong G, et al. Ultrasonography-guided fine-needle aspiration of thyroid incidentaloma: correlation with pathological findings. Clin Endocrinol (Oxf) 2004; 60:21.</a></li><li><a class="nounderline abstract_t">Boelaert K, Horacek J, Holder RL, et al. Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. J Clin Endocrinol Metab 2006; 91:4295.</a></li><li><a class="nounderline abstract_t">Haymart MR, Repplinger DJ, Leverson GE, et al. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab 2008; 93:809.</a></li><li><a class="nounderline abstract_t">McLeod DS, Cooper DS, Ladenson PW, et al. Prognosis of differentiated thyroid cancer in relation to serum thyrotropin and thyroglobulin antibody status at time of diagnosis. Thyroid 2014; 24:35.</a></li><li><a class="nounderline abstract_t">US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, et al. Screening for Thyroid Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 2017; 317:1882.</a></li><li><a class="nounderline abstract_t">Solbiati L, Volterrani L, Rizzatto G, et al. The thyroid gland with low uptake lesions: evaluation by ultrasound. Radiology 1985; 155:187.</a></li><li><a class="nounderline abstract_t">Radecki PD, Arger PH, Arenson RL, et al. Thyroid imaging: comparison of high-resolution real-time ultrasound and computed tomography. Radiology 1984; 153:145.</a></li><li><a class="nounderline abstract_t">Tan GH, Gharib H. Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Ann Intern Med 1997; 126:226.</a></li><li><a class="nounderline abstract_t">Marqusee E, Benson CB, Frates MC, et al. Usefulness of ultrasonography in the management of nodular thyroid disease. Ann Intern Med 2000; 133:696.</a></li><li><a class="nounderline abstract_t">Reschini E, Ferrari C, Castellani M, et al. The trapping-only nodules of the thyroid gland: prevalence study. Thyroid 2006; 16:757.</a></li><li><a class="nounderline abstract_t">Dige-Petersen H, Kroon S, Vadstrup S, et al. A comparison of 99Tc and 123I scintigraphy in nodular thyroid disorders. Eur J Nucl Med 1978; 3:1.</a></li><li><a class="nounderline abstract_t">Shambaugh GE 3rd, Quinn JL, Oyasu R, Freinkel N. Disparate thyroid imaging. Combined studies with sodium pertechnetate Tc 99m and radioactive iodine. JAMA 1974; 228:866.</a></li><li><a class="nounderline abstract_t">Tennvall J, Cederquist E, Möller T, et al. Preoperative scintigraphy with correlation to cytology and histopathology in carcinoma of the thyroid. Acta Radiol Oncol 1983; 22:183.</a></li><li><a class="nounderline abstract_t">Turner JW, Spencer RP. Thyroid carcinoma presenting as a pertechnetate "hot" nodule, but without 131I uptake: case report. J Nucl Med 1976; 17:22.</a></li><li><a class="nounderline abstract_t">Arnold JE, Pinsky S. Comparison of 99mTc and 123I for thyroid imaging. J Nucl Med 1976; 17:261.</a></li><li><a class="nounderline abstract_t">Blum M, Goldman AB. Improved diagnosis of "nondelineated" thyroid nodules by oblique scintillation scanning and echography. J Nucl Med 1975; 16:713.</a></li><li><a class="nounderline abstract_t">Nelson RL, Wahner HW, Gorman CA. Rectilinear thyroid scanning as a predictor of malignancy. Ann Intern Med 1978; 88:41.</a></li><li><a class="nounderline abstract_t">Miller JM. Re: thyroid carcinoma in an autonomously functioning nodule. J Nucl Med 1980; 21:296.</a></li><li><a class="nounderline abstract_t">Hoving J, Piers DA, Vermey A, Oosterhuis JW. Carcinoma in hyperfunctioning thyroid nodule in recurrent hyperthyroidism. Eur J Nucl Med 1981; 6:131.</a></li><li><a class="nounderline abstract_t">Hayes FJ, Sheahan K, Heffernan A, McKenna TJ. Aggressive thyroid cancer associated with toxic nodular goitre. Eur J Endocrinol 1996; 134:366.</a></li><li><a class="nounderline abstract_t">Ashcraft MW, Van Herle AJ. Management of thyroid nodules. II: Scanning techniques, thyroid suppressive therapy, and fine needle aspiration. Head Neck Surg 1981; 3:297.</a></li><li><a class="nounderline abstract_t">Castro MR, Gharib H. Continuing controversies in the management of thyroid nodules. Ann Intern Med 2005; 142:926.</a></li><li><a class="nounderline abstract_t">Miller JM, Hamburger JI, Kini S. Diagnosis of thyroid nodules. Use of fine-needle aspiration and needle biopsy. JAMA 1979; 241:481.</a></li><li><a class="nounderline abstract_t">Hamberger B, Gharib H, Melton LJ 3rd, et al. Fine-needle aspiration biopsy of thyroid nodules. Impact on thyroid practice and cost of care. Am J Med 1982; 73:381.</a></li><li><a class="nounderline abstract_t">Papini E, Guglielmi R, Bianchini A, et al. Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features. J Clin Endocrinol Metab 2002; 87:1941.</a></li><li><a class="nounderline abstract_t">Tessler FN, Middleton WD, Grant EG, et al. ACR Thyroid Imaging, Reporting and Data System (TI-RADS): White Paper of the ACR TI-RADS Committee. J Am Coll Radiol 2017; 14:587.</a></li><li><a class="nounderline abstract_t">Durante C, Grani G, Lamartina L, et al. The Diagnosis and Management of Thyroid Nodules: A Review. JAMA 2018; 319:914.</a></li><li><a class="nounderline abstract_t">Ha EJ, Shin JH, Na DG, et al. Comparison of the diagnostic performance of the modified Korean Thyroid Imaging Reporting and Data System for thyroid malignancy with three international guidelines. Ultrasonography 2021; 40:594.</a></li><li><a class="nounderline abstract_t">Sparano C, Verdiani V, Pupilli C, et al. Choosing the best algorithm among five thyroid nodule ultrasound scores: from performance to cytology sparing-a single-center retrospective study in a large cohort. Eur Radiol 2021; 31:5689.</a></li><li><a class="nounderline abstract_t">Eidt LB, Nunes de Oliveira C, Lagos YBB, et al. A prospective comparison of ACR-TIRADS and EU-TIRADS in thyroid nodule assessment for FNA-US. Clin Endocrinol (Oxf) 2023; 98:415.</a></li><li><a class="nounderline abstract_t">Tang AL, Falciglia M, Yang H, et al. Validation of American Thyroid Association Ultrasound Risk Assessment of Thyroid Nodules Selected for Ultrasound Fine-Needle Aspiration. Thyroid 2017; 27:1077.</a></li><li><a class="nounderline abstract_t">Kwak JY, Han KH, Yoon JH, et al. Thyroid imaging reporting and data system for US features of nodules: a step in establishing better stratification of cancer risk. Radiology 2011; 260:892.</a></li><li><a class="nounderline abstract_t">Ha EJ, Na DG, Baek JH, et al. US Fine-Needle Aspiration Biopsy for Thyroid Malignancy: Diagnostic Performance of Seven Society Guidelines Applied to 2000 Thyroid Nodules. Radiology 2018; 287:893.</a></li><li><a class="nounderline abstract_t">Grani G, Lamartina L, Ascoli V, et al. Reducing the Number of Unnecessary Thyroid Biopsies While Improving Diagnostic Accuracy: Toward the "Right" TIRADS. J Clin Endocrinol Metab 2019; 104:95.</a></li><li><a class="nounderline abstract_t">Castellana M, Castellana C, Treglia G, et al. Performance of Five Ultrasound Risk Stratification Systems in Selecting Thyroid Nodules for FNA. J Clin Endocrinol Metab 2020; 105.</a></li><li><a class="nounderline abstract_t">Staibano P, Forner D, Noel CW, et al. Ultrasonography and Fine-Needle Aspiration in Indeterminate Thyroid Nodules: A Systematic Review of Diagnostic Test Accuracy. Laryngoscope 2022; 132:242.</a></li><li><a class="nounderline abstract_t">Brito JP, Ito Y, Miyauchi A, Tuttle RM. A Clinical Framework to Facilitate Risk Stratification When Considering an Active Surveillance Alternative to Immediate Biopsy and Surgery in Papillary Microcarcinoma. Thyroid 2016; 26:144.</a></li><li><a class="nounderline abstract_t">Durante C, Costante G, Lucisano G, et al. The natural history of benign thyroid nodules. JAMA 2015; 313:926.</a></li><li><a class="nounderline abstract_t">Costante G, Filetti S. Early diagnosis of medullary thyroid carcinoma: is systematic calcitonin screening appropriate in patients with nodular thyroid disease? Oncologist 2011; 16:49.</a></li><li><a class="nounderline abstract_t">Burch HB, Burman KD, Cooper DS, et al. A 2015 Survey of Clinical Practice Patterns in the Management of Thyroid Nodules. J Clin Endocrinol Metab 2016; 101:2853.</a></li><li><a class="nounderline abstract_t">Huang TW, Lai JH, Wu MY, et al. Systematic review of clinical practice guidelines in the diagnosis and management of thyroid nodules and cancer. BMC Med 2013; 11:191.</a></li><li><a class="nounderline abstract_t">Hodak SP, Burman KD. The calcitonin conundrum--is it time for routine measurement of serum calcitonin in patients with thyroid nodules? J Clin Endocrinol Metab 2004; 89:511.</a></li><li><a class="nounderline abstract_t">Daniels GH. Screening for medullary thyroid carcinoma with serum calcitonin measurements in patients with thyroid nodules in the United States and Canada. Thyroid 2011; 21:1199.</a></li><li><a class="nounderline abstract_t">Tormey WP, Byrne B, Hill AD, et al. Should serum calcitonin be routinely measured in patients presenting with thyroid nodule? Minerva Endocrinol 2017; 42:306.</a></li><li><a class="nounderline abstract_t">Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015; 25:567.</a></li><li><a class="nounderline abstract_t">Karges W, Dralle H, Raue F, et al. Calcitonin measurement to detect medullary thyroid carcinoma in nodular goiter: German evidence-based consensus recommendation. Exp Clin Endocrinol Diabetes 2004; 112:52.</a></li><li><a class="nounderline abstract_t">Colombo C, Verga U, Mian C, et al. Comparison of calcium and pentagastrin tests for the diagnosis and follow-up of medullary thyroid cancer. J Clin Endocrinol Metab 2012; 97:905.</a></li><li><a class="nounderline abstract_t">Mian C, Perrino M, Colombo C, et al. Refining calcium test for the diagnosis of medullary thyroid cancer: cutoffs, procedures, and safety. J Clin Endocrinol Metab 2014; 99:1656.</a></li><li><a class="nounderline abstract_t">Horvit PK, Gagel RF. The goitrous patient with an elevated serum calcitonin--what to do? J Clin Endocrinol Metab 1997; 82:335.</a></li><li><a class="nounderline abstract_t">Niccoli P, Wion-Barbot N, Caron P, et al. Interest of routine measurement of serum calcitonin: study in a large series of thyroidectomized patients. The French Medullary Study Group. J Clin Endocrinol Metab 1997; 82:338.</a></li><li><a class="nounderline abstract_t">Ozgen AG, Hamulu F, Bayraktar F, et al. Evaluation of routine basal serum calcitonin measurement for early diagnosis of medullary thyroid carcinoma in seven hundred seventy-three patients with nodular goiter. Thyroid 1999; 9:579.</a></li><li><a class="nounderline abstract_t">Hahm JR, Lee MS, Min YK, et al. Routine measurement of serum calcitonin is useful for early detection of medullary thyroid carcinoma in patients with nodular thyroid diseases. Thyroid 2001; 11:73.</a></li><li><a class="nounderline abstract_t">Elisei R, Bottici V, Luchetti F, et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab 2004; 89:163.</a></li><li><a class="nounderline abstract_t">Costante G, Meringolo D, Durante C, et al. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab 2007; 92:450.</a></li><li><a class="nounderline abstract_t">Karanikas G, Moameni A, Poetzi C, et al. Frequency and relevance of elevated calcitonin levels in patients with neoplastic and nonneoplastic thyroid disease and in healthy subjects. J Clin Endocrinol Metab 2004; 89:515.</a></li><li><a class="nounderline abstract_t">Vierhapper H, Niederle B, Bieglmayer C, et al. Early diagnosis and curative therapy of medullary thyroid carcinoma by routine measurement of serum calcitonin in patients with thyroid disorders. Thyroid 2005; 15:1267.</a></li><li><a class="nounderline abstract_t">Borget I, De Pouvourville G, Schlumberger M. Editorial: Calcitonin determination in patients with nodular thyroid disease. J Clin Endocrinol Metab 2007; 92:425.</a></li><li><a class="nounderline abstract_t">Rink T, Truong PN, Schroth HJ, et al. Calculation and validation of a plasma calcitonin limit for early detection of medullary thyroid carcinoma in nodular thyroid disease. Thyroid 2009; 19:327.</a></li><li><a class="nounderline abstract_t">Herrmann BL, Schmid KW, Goerges R, et al. Calcitonin screening and pentagastrin testing: predictive value for the diagnosis of medullary carcinoma in nodular thyroid disease. Eur J Endocrinol 2010; 162:1141.</a></li><li><a class="nounderline abstract_t">Pacini F, Fontanelli M, Fugazzola L, et al. Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 1994; 78:826.</a></li><li><a class="nounderline abstract_t">Machens A, Hoffmann F, Sekulla C, Dralle H. Importance of gender-specific calcitonin thresholds in screening for occult sporadic medullary thyroid cancer. Endocr Relat Cancer 2009; 16:1291.</a></li><li><a class="nounderline abstract_t">Chambon G, Alovisetti C, Idoux-Louche C, et al. The use of preoperative routine measurement of basal serum thyrocalcitonin in candidates for thyroidectomy due to nodular thyroid disorders: results from 2733 consecutive patients. J Clin Endocrinol Metab 2011; 96:75.</a></li><li><a class="nounderline abstract_t">Verbeek HH, de Groot JWB, Sluiter WJ, et al. Calcitonin testing for detection of medullary thyroid cancer in people with thyroid nodules. Cochrane Database Syst Rev 2020; 3:CD010159.</a></li><li><a class="nounderline abstract_t">Machens A, Dralle H. Biological relevance of medullary thyroid microcarcinoma. J Clin Endocrinol Metab 2012; 97:1547.</a></li><li><a class="nounderline abstract_t">Toledo SP, Lourenço DM Jr, Santos MA, et al. Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma. Clinics (Sao Paulo) 2009; 64:699.</a></li><li><a class="nounderline abstract_t">Erdogan MF, Gursoy A, Kulaksizoglu M. Long-term effects of elevated gastrin levels on calcitonin secretion. J Endocrinol Invest 2006; 29:771.</a></li><li><a class="nounderline abstract_t">Wang TS, Ocal IT, Sosa JA, et al. Medullary thyroid carcinoma without marked elevation of calcitonin: a diagnostic and surveillance dilemma. Thyroid 2008; 18:889.</a></li><li><a class="nounderline abstract_t">Dora JM, Canalli MH, Capp C, et al. Normal perioperative serum calcitonin levels in patients with advanced medullary thyroid carcinoma: case report and review of the literature. Thyroid 2008; 18:895.</a></li><li><a class="nounderline abstract_t">Silva de Morais N, Stuart J, Guan H, et al. The Impact of Hashimoto Thyroiditis on Thyroid Nodule Cytology and Risk of Thyroid Cancer. J Endocr Soc 2019; 3:791.</a></li><li><a class="nounderline abstract_t">Clark OH. TSH suppression in the management of thyroid nodules and thyroid cancer. World J Surg 1981; 5:39.</a></li><li><a class="nounderline abstract_t">Schneider AB, Bekerman C, Leland J, et al. Thyroid nodules in the follow-up of irradiated individuals: comparison of thyroid ultrasound with scanning and palpation. J Clin Endocrinol Metab 1997; 82:4020.</a></li><li><a class="nounderline abstract_t">Van den Bruel A, Maes A, De Potter T, et al. Clinical relevance of thyroid fluorodeoxyglucose-whole body positron emission tomography incidentaloma. J Clin Endocrinol Metab 2002; 87:1517.</a></li><li><a class="nounderline abstract_t">Nam SY, Roh JL, Kim JS, et al. Focal uptake of (18)F-fluorodeoxyglucose by thyroid in patients with nonthyroidal head and neck cancers. Clin Endocrinol (Oxf) 2007; 67:135.</a></li><li><a class="nounderline abstract_t">Taywade SK, Damle NA, Bal C. PSMA Expression in Papillary Thyroid Carcinoma: Opening a New Horizon in Management of Thyroid Cancer? Clin Nucl Med 2016; 41:e263.</a></li><li><a class="nounderline abstract_t">Soelberg KK, Bonnema SJ, Brix TH, Hegedüs L. Risk of malignancy in thyroid incidentalomas detected by 18F-fluorodeoxyglucose positron emission tomography: a systematic review. Thyroid 2012; 22:918.</a></li><li><a class="nounderline abstract_t">Merten MM, Castro MR, Zhang J, et al. Examining the Role of Preoperative Positron Emission Tomography/Computerized Tomography in Combination with Ultrasonography in Discriminating Benign from Malignant Cytologically Indeterminate Thyroid Nodules. Thyroid 2017; 27:95.</a></li><li><a class="nounderline abstract_t">Kim WB, Han SM, Kim TY, et al. Ultrasonographic screening for detection of thyroid cancer in patients with Graves' disease. Clin Endocrinol (Oxf) 2004; 60:719.</a></li><li><a class="nounderline abstract_t">Kwak JY, Koo H, Youk JH, et al. Value of US correlation of a thyroid nodule with initially benign cytologic results. Radiology 2010; 254:292.</a></li><li><a class="nounderline abstract_t">Yassa L, Cibas ES, Benson CB, et al. Long-term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation. Cancer 2007; 111:508.</a></li><li><a class="nounderline abstract_t">Wang CC, Friedman L, Kennedy GC, et al. A large multicenter correlation study of thyroid nodule cytopathology and histopathology. Thyroid 2011; 21:243.</a></li><li><a class="nounderline abstract_t">Ali SZ, Baloch ZW, Cochand-Priollet B, et al. The 2023 Bethesda System for Reporting Thyroid Cytopathology. Thyroid 2023; 33:1039.</a></li><li><a class="nounderline abstract_t">Kuma K, Matsuzuka F, Yokozawa T, et al. Fate of untreated benign thyroid nodules: results of long-term follow-up. World J Surg 1994; 18:495.</a></li><li><a class="nounderline abstract_t">Lucas A, Llatjós M, Salinas I, et al. Fine-needle aspiration cytology of benign nodular thyroid disease. Value of re-aspiration. Eur J Endocrinol 1995; 132:677.</a></li><li><a class="nounderline abstract_t">Merchant SH, Izquierdo R, Khurana KK. Is repeated fine-needle aspiration cytology useful in the management of patients with benign nodular thyroid disease? Thyroid 2000; 10:489.</a></li><li><a class="nounderline abstract_t">Erdoğan MF, Kamel N, Aras D, et al. Value of re-aspirations in benign nodular thyroid disease. Thyroid 1998; 8:1087.</a></li><li><a class="nounderline abstract_t">Orlandi A, Puscar A, Capriata E, Fideleff H. Repeated fine-needle aspiration of the thyroid in benign nodular thyroid disease: critical evaluation of long-term follow-up. Thyroid 2005; 15:274.</a></li><li><a class="nounderline abstract_t">Kim SY, Han KH, Moon HJ, et al. Thyroid nodules with benign findings at cytologic examination: results of long-term follow-up with US. Radiology 2014; 271:272.</a></li><li><a class="nounderline abstract_t">Alexander EK, Hurwitz S, Heering JP, et al. Natural history of benign solid and cystic thyroid nodules. Ann Intern Med 2003; 138:315.</a></li><li><a class="nounderline abstract_t">Angell TE, Vyas CM, Medici M, et al. Differential Growth Rates of Benign vs. Malignant Thyroid Nodules. J Clin Endocrinol Metab 2017; 102:4642.</a></li><li><a class="nounderline abstract_t">Nou E, Kwong N, Alexander LK, et al. Determination of the optimal time interval for repeat evaluation after a benign thyroid nodule aspiration. J Clin Endocrinol Metab 2014; 99:510.</a></li><li><a class="nounderline abstract_t">Adam MA, Thomas S, Youngwirth L, et al. Is There a Minimum Number of Thyroidectomies a Surgeon Should Perform to Optimize Patient Outcomes? Ann Surg 2016.</a></li><li><a class="nounderline abstract_t">Orloff LA, Noel JE, Stack BC Jr, et al. Radiofrequency ablation and related ultrasound-guided ablation technologies for treatment of benign and malignant thyroid disease: An international multidisciplinary consensus statement of the American Head and Neck Society Endocrine Surgery Section with the Asia Pacific Society of Thyroid Surgery, Associazione Medici Endocrinologi, British Association of Endocrine and Thyroid Surgeons, European Thyroid Association, Italian Society of Endocrine Surgery Units, Korean Society of Thyroid Radiology, Latin American Thyroid Society, and Thyroid Nodules Therapies Association. Head Neck 2022; 44:633.</a></li><li><a class="nounderline abstract_t">Noel JE, Sinclair CF. Radiofrequency Ablation for Benign Thyroid Nodules. J Clin Endocrinol Metab 2023; 109:e12.</a></li><li><a class="nounderline abstract_t">Chorti A, Bontinis V, Tzikos G, et al. Minimally Invasive Treatments of Benign Thyroid Nodules: A Network Meta-Analysis of Short-Term Outcomes. Thyroid 2023; 33:950.</a></li><li><a class="nounderline abstract_t">Jeong SY, Ha EJ, Baek JH, et al. Assessment of thyroid-specific quality of life in patients with benign symptomatic thyroid nodules treated with radiofrequency or ethanol ablation: a prospective multicenter study. Ultrasonography 2022; 41:204.</a></li><li><a class="nounderline abstract_t">Jawad S, Morley S, Otero S, et al. Ultrasound-guided radiofrequency ablation (RFA) of benign symptomatic thyroid nodules - initial UK experience. Br J Radiol 2019; 92:20190026.</a></li><li><a class="nounderline abstract_t">Pacella CM, Mauri G, Achille G, et al. Outcomes and Risk Factors for Complications of Laser Ablation for Thyroid Nodules: A Multicenter Study on 1531 Patients. J Clin Endocrinol Metab 2015; 100:3903.</a></li><li><a class="nounderline abstract_t">Baek JH, Lee JH, Sung JY, et al. Complications encountered in the treatment of benign thyroid nodules with US-guided radiofrequency ablation: a multicenter study. Radiology 2012; 262:335.</a></li><li><a class="nounderline abstract_t">Russ G, Ben Hamou A, Poirée S, et al. Learning curve for radiofrequency ablation of benign thyroid nodules. Int J Hyperthermia 2021; 38:55.</a></li><li><a class="nounderline abstract_t">Tuttle RM, Zhang L, Shaha A. A clinical framework to facilitate selection of patients with differentiated thyroid cancer for active surveillance or less aggressive initial surgical management. Expert Rev Endocrinol Metab 2018; 13:77.</a></li><li><a class="nounderline abstract_t">Sasaki T, Miyauchi A, Fujishima M, et al. Comparison of Postoperative Unfavorable Events in Patients with Low-Risk Papillary Thyroid Carcinoma: Immediate Surgery Versus Conversion Surgery Following Active Surveillance. Thyroid 2023; 33:186.</a></li><li><a class="nounderline abstract_t">Alexander EK, Heering JP, Benson CB, et al. Assessment of nondiagnostic ultrasound-guided fine needle aspirations of thyroid nodules. J Clin Endocrinol Metab 2002; 87:4924.</a></li><li><a class="nounderline abstract_t">Samir AE, Vij A, Seale MK, et al. Ultrasound-guided percutaneous thyroid nodule core biopsy: clinical utility in patients with prior nondiagnostic fine-needle aspirate. Thyroid 2012; 22:461.</a></li><li><a class="nounderline abstract_t">Moon HJ, Kwak JY, Choi YS, Kim EK. How to manage thyroid nodules with two consecutive non-diagnostic results on ultrasonography-guided fine-needle aspiration. World J Surg 2012; 36:586.</a></li><li><a class="nounderline abstract_t">Jack GA, Sternberg SB, Aronson MD, et al. Nondiagnostic Fine-Needle Aspiration Biopsy of Thyroid Nodules: Outcomes and Determinants. Thyroid 2020; 30:992.</a></li></ol></div><div id="topicVersionRevision">Topic 7890 Version 63.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6703815" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Cancer in thyroid nodules. A community hospital survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2773619" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : High frequency of cancer in cold thyroid nodules occurring at young age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15496625" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Clinical practice. The thyroid nodule.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16053388" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Thyroid cancer in the thyroid nodules evaluated by ultrasonography and fine-needle aspiration cytology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26465395" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The Influence of Patient Age on Thyroid Nodule Formation, Multinodularity, and Thyroid Cancer Risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26465395" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The Influence of Patient Age on Thyroid Nodule Formation, Multinodularity, and Thyroid Cancer Risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26462967" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16230549" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The significance of incidental thyroid abnormalities identified during carotid duplex ultrasonography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9848711" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Role of ultrasound-guided fine-needle aspiration biopsy in evaluation of nonpalpable thyroid nodules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9920057" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Indications and limits of ultrasound-guided cytology in the management of nonpalpable thyroid nodules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14678283" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Ultrasonography-guided fine-needle aspiration of thyroid incidentaloma: correlation with pathological findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16868053" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18160464" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23731273" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Prognosis of differentiated thyroid cancer in relation to serum thyrotropin and thyroglobulin antibody status at time of diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28492905" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Screening for Thyroid Cancer: US Preventive Services Task Force Recommendation Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3883413" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The thyroid gland with low uptake lesions: evaluation by ultrasound.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6473776" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Thyroid imaging: comparison of high-resolution real-time ultrasound and computed tomography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9027275" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11074902" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Usefulness of ultrasonography in the management of nodular thyroid disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16910877" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The trapping-only nodules of the thyroid gland: prevalence study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/753616" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : A comparison of 99Tc and 123I scintigraphy in nodular thyroid disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4406304" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Disparate thyroid imaging. Combined studies with sodium pertechnetate Tc 99m and radioactive iodine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6312757" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Preoperative scintigraphy with correlation to cytology and histopathology in carcinoma of the thyroid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1244441" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Thyroid carcinoma presenting as a pertechnetate "hot" nodule, but without 131I uptake: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1255250" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Comparison of 99mTc and 123I for thyroid imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1177047" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Improved diagnosis of "nondelineated" thyroid nodules by oblique scintillation scanning and echography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/619756" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Rectilinear thyroid scanning as a predictor of malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7365528" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Re: thyroid carcinoma in an autonomously functioning nodule.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7215376" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Carcinoma in hyperfunctioning thyroid nodule in recurrent hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8616537" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Aggressive thyroid cancer associated with toxic nodular goitre.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6163751" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Management of thyroid nodules. II: Scanning techniques, thyroid suppressive therapy, and fine needle aspiration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15941700" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Continuing controversies in the management of thyroid nodules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/366189" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Diagnosis of thyroid nodules. Use of fine-needle aspiration and needle biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7124765" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Fine-needle aspiration biopsy of thyroid nodules. Impact on thyroid practice and cost of care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11994321" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28372962" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : ACR Thyroid Imaging, Reporting and Data System (TI-RADS): White Paper of the ACR TI-RADS Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29509871" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The Diagnosis and Management of Thyroid Nodules: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34044490" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Comparison of the diagnostic performance of the modified Korean Thyroid Imaging Reporting and Data System for thyroid malignancy with three international guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33599836" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Choosing the best algorithm among five thyroid nodule ultrasound scores: from performance to cytology sparing-a single-center retrospective study in a large cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35864563" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : A prospective comparison of ACR-TIRADS and EU-TIRADS in thyroid nodule assessment for FNA-US.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28657511" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Validation of American Thyroid Association Ultrasound Risk Assessment of Thyroid Nodules Selected for Ultrasound Fine-Needle Aspiration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21771959" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Thyroid imaging reporting and data system for US features of nodules: a step in establishing better stratification of cancer risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29465333" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : US Fine-Needle Aspiration Biopsy for Thyroid Malignancy: Diagnostic Performance of Seven Society Guidelines Applied to 2000 Thyroid Nodules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30299457" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Reducing the Number of Unnecessary Thyroid Biopsies While Improving Diagnostic Accuracy: Toward the "Right" TIRADS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31690937" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Performance of Five Ultrasound Risk Stratification Systems in Selecting Thyroid Nodules for FNA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34411290" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Ultrasonography and Fine-Needle Aspiration in Indeterminate Thyroid Nodules: A Systematic Review of Diagnostic Test Accuracy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26414743" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : A Clinical Framework to Facilitate Risk Stratification When Considering an Active Surveillance Alternative to Immediate Biopsy and Surgery in Papillary Microcarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25734734" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The natural history of benign thyroid nodules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21212427" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Early diagnosis of medullary thyroid carcinoma: is systematic calcitonin screening appropriate in patients with nodular thyroid disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27014951" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : A 2015 Survey of Clinical Practice Patterns in the Management of Thyroid Nodules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23987922" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Systematic review of clinical practice guidelines in the diagnosis and management of thyroid nodules and cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14764754" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The calcitonin conundrum--is it time for routine measurement of serum calcitonin in patients with thyroid nodules?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21936671" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Screening for medullary thyroid carcinoma with serum calcitonin measurements in patients with thyroid nodules in the United States and Canada.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28092147" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Should serum calcitonin be routinely measured in patients presenting with thyroid nodule?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25810047" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14758572" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Calcitonin measurement to detect medullary thyroid carcinoma in nodular goiter: German evidence-based consensus recommendation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22170709" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Comparison of calcium and pentagastrin tests for the diagnosis and follow-up of medullary thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24552221" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Refining calcium test for the diagnosis of medullary thyroid cancer: cutoffs, procedures, and safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9024212" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The goitrous patient with an elevated serum calcitonin--what to do?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9024213" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Interest of routine measurement of serum calcitonin: study in a large series of thyroidectomized patients. The French Medullary Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10411120" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Evaluation of routine basal serum calcitonin measurement for early diagnosis of medullary thyroid carcinoma in seven hundred seventy-three patients with nodular goiter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11272100" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Routine measurement of serum calcitonin is useful for early detection of medullary thyroid carcinoma in patients with nodular thyroid diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14715844" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17119000" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14764755" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Frequency and relevance of elevated calcitonin levels in patients with neoplastic and nonneoplastic thyroid disease and in healthy subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16356091" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Early diagnosis and curative therapy of medullary thyroid carcinoma by routine measurement of serum calcitonin in patients with thyroid disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17284646" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Editorial: Calcitonin determination in patients with nodular thyroid disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19355822" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Calculation and validation of a plasma calcitonin limit for early detection of medullary thyroid carcinoma in nodular thyroid disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20332126" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Calcitonin screening and pentagastrin testing: predictive value for the diagnosis of medullary carcinoma in nodular thyroid disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8157706" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19726541" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Importance of gender-specific calcitonin thresholds in screening for occult sporadic medullary thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20881258" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : The use of preoperative routine measurement of basal serum thyrocalcitonin in candidates for thyroidectomy due to nodular thyroid disorders: results from 2733 consecutive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32176812" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Calcitonin testing for detection of medullary thyroid cancer in people with thyroid nodules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22399508" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Biological relevance of medullary thyroid microcarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19606248" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17114906" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Long-term effects of elevated gastrin levels on calcitonin secretion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18651827" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Medullary thyroid carcinoma without marked elevation of calcitonin: a diagnostic and surveillance dilemma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18651801" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Normal perioperative serum calcitonin levels in patients with advanced medullary thyroid carcinoma: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30963137" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : The Impact of Hashimoto Thyroiditis on Thyroid Nodule Cytology and Risk of Thyroid Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7233954" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : TSH suppression in the management of thyroid nodules and thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9398706" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Thyroid nodules in the follow-up of irradiated individuals: comparison of thyroid ultrasound with scanning and palpation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11932274" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Clinical relevance of thyroid fluorodeoxyglucose-whole body positron emission tomography incidentaloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17465995" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Focal uptake of (18)F-fluorodeoxyglucose by thyroid in patients with nonthyroidal head and neck cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26914556" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : PSMA Expression in Papillary Thyroid Carcinoma: Opening a New Horizon in Management of Thyroid Cancer?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22827552" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Risk of malignancy in thyroid incidentalomas detected by 18F-fluorodeoxyglucose positron emission tomography: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27762671" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Examining the Role of Preoperative Positron Emission Tomography/Computerized Tomography in Combination with Ultrasonography in Discriminating Benign from Malignant Cytologically Indeterminate Thyroid Nodules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15163336" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Ultrasonographic screening for detection of thyroid cancer in patients with Graves' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20019136" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Value of US correlation of a thyroid nodule with initially benign cytologic results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17999413" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Long-term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21190442" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : A large multicenter correlation study of thyroid nodule cytopathology and histopathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37427847" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : The 2023 Bethesda System for Reporting Thyroid Cytopathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7725734" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Fate of untreated benign thyroid nodules: results of long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7788005" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Fine-needle aspiration cytology of benign nodular thyroid disease. Value of re-aspiration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10907992" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Is repeated fine-needle aspiration cytology useful in the management of patients with benign nodular thyroid disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9920362" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Value of re-aspirations in benign nodular thyroid disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15785247" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Repeated fine-needle aspiration of the thyroid in benign nodular thyroid disease: critical evaluation of long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24475857" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Thyroid nodules with benign findings at cytologic examination: results of long-term follow-up with US.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12585829" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Natural history of benign solid and cystic thyroid nodules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29040691" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Differential Growth Rates of Benign vs. Malignant Thyroid Nodules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24276452" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Determination of the optimal time interval for repeat evaluation after a benign thyroid nodule aspiration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26967630" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Is There a Minimum Number of Thyroidectomies a Surgeon Should Perform to Optimize Patient Outcomes?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34939714" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Radiofrequency ablation and related ultrasound-guided ablation technologies for treatment of benign and malignant thyroid disease: An international multidisciplinary consensus statement of the American Head and Neck Society Endocrine Surgery Section with the Asia Pacific Society of Thyroid Surgery, Associazione Medici Endocrinologi, British Association of Endocrine and Thyroid Surgeons, European Thyroid Association, Italian Society of Endocrine Surgery Units, Korean Society of Thyroid Radiology, Latin American Thyroid Society, and Thyroid Nodules Therapies Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37401778" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Radiofrequency Ablation for Benign Thyroid Nodules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37166390" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Minimally Invasive Treatments of Benign Thyroid Nodules: A Network Meta-Analysis of Short-Term Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34517695" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Assessment of thyroid-specific quality of life in patients with benign symptomatic thyroid nodules treated with radiofrequency or ethanol ablation: a prospective multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31084496" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Ultrasound-guided radiofrequency ablation (RFA) of benign symptomatic thyroid nodules - initial UK experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26274342" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Outcomes and Risk Factors for Complications of Laser Ablation for Thyroid Nodules: A Multicenter Study on 1531 Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21998044" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Complications encountered in the treatment of benign thyroid nodules with US-guided radiofrequency ablation: a multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33491515" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Learning curve for radiofrequency ablation of benign thyroid nodules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30058863" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : A clinical framework to facilitate selection of patients with differentiated thyroid cancer for active surveillance or less aggressive initial surgical management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36205580" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Comparison of Postoperative Unfavorable Events in Patients with Low-Risk Papillary Thyroid Carcinoma: Immediate Surgery Versus Conversion Surgery Following Active Surveillance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12414851" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Assessment of nondiagnostic ultrasound-guided fine needle aspirations of thyroid nodules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22304390" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Ultrasound-guided percutaneous thyroid nodule core biopsy: clinical utility in patients with prior nondiagnostic fine-needle aspirate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22228400" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : How to manage thyroid nodules with two consecutive non-diagnostic results on ultrasonography-guided fine-needle aspiration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31950884" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Nondiagnostic Fine-Needle Aspiration Biopsy of Thyroid Nodules: Outcomes and Determinants.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
